The usefulness of CYFRA 21-1 to diagnose and predict preeclampsia: A nested case-control study

BMC Pregnancy and Childbirth

Volumn 16, Issue 1, 2016, Pages

  Kuessel, Lorenz ^a   Zeisler, Harald ^a   Ristl, Robin ^b   Binder, Julia ^a,c   Pateisky, Petra ^a   Schmid, Maximilian ^a   Marschalek, Julian ^a   Perkmann, Thomas ^b   Haslacher, Helmuth ^b   Husslein, Heinrich ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

CYFRA 21 1; Cytokeratin 19; Diagnosis; Endothelial dysfunction; Prediction; Preeclampsia

Indexed keywords

CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 21 1; UNCLASSIFIED DRUG; ANTIGEN CYFRA21.1; BIOLOGICAL MARKER; CYTOKERATIN 19; TUMOR ANTIGEN;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOTHELIAL DYSFUNCTION; FEMALE; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; PREECLAMPSIA; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; EVALUATION STUDY; LONGITUDINAL STUDY; MATERNAL SERUM SCREENING TEST; PRE-ECLAMPSIA; PREDICTIVE VALUE; PREGNANCY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIGENS, NEOPLASM; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; KERATIN-19; LONGITUDINAL STUDIES; MATERNAL SERUM SCREENING TESTS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTERS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 85009266737     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/s12884-016-1132-4     Document Type: Article

References (33)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-44.
2. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ. 2001;322:1089-93. discussion 1093-1084.
3. Hahn S, Huppertz B, Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? Placenta. 2005;26:515-26.
4. Myatt L. Role of placenta in preeclampsia. Endocrine. 2002;19:103-11.
5. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW. New consensus nomenclature for mammalian keratins. J Cell Biol. 2006;174:169-74.
6. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-904.
7. Schmidt M, Hoffmann B, Beelen D, Gellhaus A, Winterhager E, Kimmig R, Kasimir-Bauer S. Detection of circulating trophoblast particles in peripheral maternal blood in preeclampsia complicated pregnancies. Hypertens Pregnancy. 2008;27:131-42.
8. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer. 2013;80:45-9.
9. Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N, et al. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumour Biol. 1995;16:345-52.
10. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res. 2000;6:4249-52.
11. Sharma SK, Bhat S, Chandel V, Sharma M, Sharma P, Gupta S, Sharma S, Bhat AA. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer. J Carcinog. 2015;14:7.
12. Yang DW, Zhang Y, Hong QY, Hu J, Li C, Pan BS, Wang Q, Ding FH, Ou JX, Liu FL, et al. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer. 2015;121 Suppl 17:3113-21.
13. Cui C, Sun X, Zhang J, Han D, Gu J. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. J Cancer Res Ther. 2014;10(Suppl):C131-4.
14. Longtine MS, Chen B, Odibo AO, Zhong Y, Nelson DM. Villous trophoblast apoptosis is elevated and restricted to cytotrophoblasts in pregnancies complicated by preeclampsia, IUGR, or preeclampsia with IUGR. Placenta. 2012;33:352-9.
15. Huppertz B, Kadyrov M, Kingdom JC. Apoptosis and its role in the trophoblast. Am J Obstet Gynecol. 2006;195:29-39.
16. Musci TJ, Roberts JM, Rodgers GM, Taylor RN. Mitogenic activity is increased in the sera of preeclamptic women before delivery. Am J Obstet Gynecol. 1988;159:1446-51.
17. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200-4.
18. Schrocksnadel H, Daxenbichler G, Artner E, Steckel-Berger G, Dapunt O. Tissue polypeptide antigen and pre-eclampsia. Lancet. 1992;340:53-4.
19. Tempfer CB, Bancher-Todesca D, Zeisler H, Schatten C, Husslein P, Gregg AR. Placental expression and serum concentrations of cytokeratin 19 in preeclampsia. Obstet Gynecol. 2000;95:677-82.
20. Kuessel L, Wild J, Haslacher H, Perkmann T, Ristl R, Zeisler H, Schmid M. Urine and serum concentrations of Cytokeratin 19 in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2014;181:311-5.
21. Li XL, Dong X, Xue Y, Li CF, Gou WL, Chen Q. Increased expression levels of E-cadherin, cytokeratin 18 and 19 observed in preeclampsia were not correlated with disease severity. Placenta. 2014;35:625-31.
22. Bulletins--Obstetrics ACoP: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159-67.
23. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22:143-8.
24. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99:547-53.
25. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161. e161-161 e111.
26. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346-52.
27. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374:13-22.
28. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31:33-46.
29. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63:534-43.
30. Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol. 1988;159:908-14.
31. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG. 2010;117:314-20.
32. Suwaki N, Masuyama H, Nakatsukasa H, Masumoto A, Sumida Y, Takamoto N, Hiramatrsu Y. Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. Am J Obstet Gynecol. 2006;195:1687-92.
33. Zera CA, Seely EW, Wilkins-Haug LE, Lim KH, Parry SI, McElrath TF. The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. Am J Obstet Gynecol. 2014;211(247):e241-247.